Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02659618 · ClinicalTrials.gov registry record
Identification of Serum Biomarkers for CD15+ Hypodense Neutrophils in Severe Asthma
A clinical trial of Severe Persistent Asthma, sponsored by Rush University Medical Center.
- Completed
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT02659618 is a study of Severe Persistent Asthma that has completed, run by Rush University Medical Center. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02659618, a study of Severe Persistent Asthma, has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to identify a serum biomarker(s) that can detect increased levels of a population of CD15+ hypodense neutrophils termed low-density granulocytes (LDG) in the blood of patients with severe persistent asthma.
Conditions Studied
Study Locations (1)
Illinois
- University Consultants in Allergy/Immunology - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-04 |
| Est. Completion | 2020-12-16 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02659618
The ClinicalTrials.gov registry entry for NCT02659618 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Severe Persistent Asthma appearing as the primary indexed condition, and to 0 interventions.
NCT02659618 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT02659618 about?
NCT02659618 is a clinical study titled "Identification of Serum Biomarkers for CD15+ Hypodense Neutrophils in Severe Asthma". The goal of this study is to identify a serum biomarker(s) that can detect increased levels of a population of CD15+ hypodense neutrophils termed low-density granulocytes (LDG) in the blood of patients with severe persistent asthma.
What is the current status of trial NCT02659618?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2016-04. Estimated completion is 2020-12-16.
What conditions does trial NCT02659618 study?
This clinical trial studies the following conditions: Severe Persistent Asthma.
Who is sponsoring clinical trial NCT02659618?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02659618 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.